1. Home
  2. GWRS vs RCEL Comparison

GWRS vs RCEL Comparison

Compare GWRS & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Water Resources Inc.

GWRS

Global Water Resources Inc.

HOLD

Current Price

$7.50

Market Cap

250.1M

Sector

Utilities

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$4.19

Market Cap

132.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GWRS
RCEL
Founded
2003
N/A
Country
United States
United States
Employees
N/A
226
Industry
Water Supply
Medical/Dental Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
250.1M
132.0M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
GWRS
RCEL
Price
$7.50
$4.19
Analyst Decision
Hold
Buy
Analyst Count
1
5
Target Price
N/A
$7.88
AVG Volume (30 Days)
84.5K
201.9K
Earning Date
03-04-2026
05-07-2026
Dividend Yield
4.05%
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$41,914,000.00
N/A
Revenue This Year
$11.31
$21.69
Revenue Next Year
$14.87
$49.58
P/E Ratio
$68.18
N/A
Revenue Growth
8.51
N/A
52 Week Low
$7.12
$3.22
52 Week High
$11.24
$10.28

Technical Indicators

Market Signals
Indicator
GWRS
RCEL
Relative Strength Index (RSI) 33.58 42.40
Support Level N/A $3.98
Resistance Level $8.88 $4.57
Average True Range (ATR) 0.38 0.32
MACD -0.10 -0.10
Stochastic Oscillator 18.35 6.99

Price Performance

Historical Comparison
GWRS
RCEL

About GWRS Global Water Resources Inc.

Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: